You searched for D - Page 3 of 43

Study shows link between prophylactic dressing use and reduction in pressure injury rates

August 30, 2017February 25, 2020 Wound Care Advisor

A new study shows a clear association between the prophylactic use of five-layer foam sacral dressings and reductions in pressure injury rates. Specifically, the study looked at the prophylactic use of Mölnlycke’s Mepilex® Border Sacrum dressing in the acute care setting over a six-year period (2010-2015). (more…)

Hope for first drug against lymphedema

August 30, 2017February 25, 2020 Wound Care Advisor

lymphedema drug against breast cancer medicine wca

Many cancer patients, especially those who’ve undergone breast cancer treatment, experience painful, swollen limbs, a condition called lymphedema.

Now researchers say they’ve found an underlying mechanism that could eventually lead to the first drug therapy for the debilitating condition. (more…)

Cervical Biopsy more efficient, less painful via new method

August 23, 2017February 25, 2020 Wound Care Advisor

Can new tool make cervical biopsy more efficient, less painful

Physicians evaluate new device to test for cervical cancer. Comparison of Tissue Yield Using Frictional Fabric Brush Versus Sharp Curettage For Endocervical Curettage.

Women undergoing cervical biopsies might have lower odds of repeat tests with a rotating fabric brush than a sharp instrument because the soft device may capture more cells for analysis, a recent study suggests. Furthermore, biopsies with the softer tool may be less painful, researchers say. Cervical biopsies sometimes fail to collect enough cells from the cervix to accurately test for cancer, in which case another biopsy is needed. (more…)

Scientists Seek People with Primary Progressive MS and Other Forms of MS to Study Gut Bacteria

August 23, 2017February 25, 2020 Wound Care Advisor

Volunteers are being sought for a major study to help determine how the gut microbiome can be used to treat multiple sclerosis, lupus, and other diseases.

Investigators at the University of California in San Francisco are recruiting people with MS for an international study of the gut microbiome – the population of bacteria in the gut – in MS. They are seeking people with primary progressive MS nationwide (there is no need for onsite visits), as well as people with any other type of MS who can make a one-time visit to San Francisco, New York, Boston or Pittsburgh. The overall purpose of these studies is to investigate the potential role of gut bacteria in MS.

Scientists Focus on Gut Flora for Future Treatments of Autoimmune Diseases

(more…)

Nurses, Doctors and Hospitals use Google Glass

August 20, 2017February 25, 2020 Wound Care Advisor

nurses doctors hospitals use google glass

For surgical collaboration; rural telemedicine, nurses and doctors at Hospitals use Google Glass. Indianapolis-based Hodei Technology is bringing Glass to hospitals in two different ways: as a tool for surgeons to teach, communicate, and collaborate (via a product called Ikasi) and, via a product called Gemini, as a new kind of telemedicine, which CEO Guy Mascaro describes as “first person point-of-view telepresence”.

A lot of people think Google Glass, the tech company’s experiment with augmented reality and wearable computing, died when the Glass Explorer program closed up shop in 2015. In fact, the technology has continued to find a home with enterprise applications, particularly in healthcare. (more…)

Gene Therapy for Non-Healing Diabetic Foot Ulcers Starts Phase III Trial

August 20, 2017February 25, 2020 Wound Care Advisor

Safety and Efficacy Study of VM202 in the Treatment of Chronic Non-Healing Foot Ulcers. This study will assess the safety and efficacy of using gene therapy via intramuscular injections of the calf for patients with chronic non-healing foot ulcers.

The first patient has been dosed in a Phase III trial assessing ViroMed’s VM202, the first pivotal study of a gene therapy indicated for patients with nonhealing diabetic foot ulcers (NHU) and concomitant peripheral artery disease (PAD).

The Phase III trial (NCT02563522) is a double-blind, placebo-controlled, multicenter study designed to evaluate VM202 for safety and efficacy in 300 adults with a diabetic foot ulcer and concomitant PAD. Two hundred patients will be randomized to VM202 and the other 100 to placebo, ViroMed’s U.S. division VM BioPharma said yesterday. (more…)